Arcutis Biotherapeutics, Inc. (ARQT) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 1:50 PM EDT
Company Participants
Todd Watanabe – President, CEO & Director
Latha Vairavan – Senior VP & Chief Financial Officer
Patrick Burnett – Executive VP & Chief Medical Officer
Conference Call Participants
Judah Frommer – Morgan Stanley, Research Division
Presentation
Judah Frommer
Morgan Stanley, Research Division
All right. Good afternoon, everyone. Welcome to the session of the Morgan Stanley Global Healthcare Conference. I’m Judah Frommer, one of the SMID biotech analysts here. We’re very excited to have the team from Arcutis joining us. Let me just get through a quick disclosure before we get started. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. With questions, please contact your Morgan Stanley sales representative.
Right. So with that out of the way, Frank, I thought we could start with a brief history of Arcutis. The company is celebrating its 10-year anniversary. So maybe just a couple of minutes on how the team, the pipeline and the commercial effort came together?
Question-and-Answer Session
Todd Watanabe
President, CEO & Director
Yes. So we just celebrated our 10th anniversary in June, and I have my 10th anniversary in like 6 weeks. I think it’s coming out pretty fast. So the company was actually founded by Frazier Healthcare. They saw an opportunity in the dermatology space where there wasn’t a lot of innovation happening at that point in time, and they thought that there was a good opportunity. So they created the company. They hired our founder, David Osborne and said, invent a dermatology product. And so David went down in his basement. He literally has a laboratory in his basement and invented what became ZORYVE. And the minute he came up with ZORYVE, they thought, okay, well, we’ve got a company now. And so they hired a dermatologist and myself and the 3 of
